Immutep (ASX:IMM) Secures €1.36 Million Under France's Research Tax Credit Program

Aditi Sarkar

28 October 2026 02:35 PM AEDT

Immutep (ASX:IMM) Secures €1.36 Million Under France's Research Tax Credit Program

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Immutep received €1.36 million (about A$2.16 million) from the French Government under the Crédit d'Impôt Recherche (CIR) program.
The payment covers eligible R&D activities carried out in calendar year 2025.
It follows an A$0.86 million Australian R&D Tax Incentive rebate announced on 30 September 2026.
Expected cash reach extends into the first half of CY2028.

Immutep Limited (ASX:IMM; NASDAQ:IMMP) has received a cash payment of €1.36 million, or about A$2.16 million, from the French Government under its Crédit d'Impôt Recherche (CIR) program. The non-dilutive funding relates to eligible research and development activities conducted during calendar year 2025.

How the French CIR Program Works

The CIR program refunds 30% of eligible R&D expenditure. Immutep qualifies through its French subsidiary, Immutep S.A.S., which conducts research at its laboratory in France.

The latest payment adds to the A$0.86 million Australian R&D Tax Incentive rebate announced on 30 September 2026. Immutep's German subsidiary, Immutep GmbH, is also eligible for Germany's R&D tax incentive, known as the Forschungszulage.

Supporting the Clinical Pipeline

Immutep said the funding will support current research and development for its product candidates, eftilagimod alfa (efti) and IMP761. Because the funds come from government incentives rather than share issues, they do not dilute existing shareholders.

The company stated that its expected cash reach extends into the first half of calendar year 2028.

About Immutep's LAG-3 Focus

Immutep is a clinical-stage biotechnology company developing immunotherapies for cancer and autoimmune disease. It is a pioneer in LAG-3-related therapeutics, with a diversified portfolio that can either stimulate or suppress the immune response.

The release included forward-looking statements and noted risks including clinical trial outcomes, an ongoing root cause analysis, manufacturing, regulatory developments, partnering discussions and the need for additional funding.

Key Takeaways

Immutep received about A$2.16 million in non-dilutive funding from France's CIR program.
Together with the recent Australian rebate, R&D incentives continue to support the company's cash position.
Funds are directed to efti and IMP761 research and development.
Cash reach is expected to extend into the first half of CY2028.

FAQs

Q: How much did Immutep receive from the French Government?

A: Immutep received €1.36 million, or about A$2.16 million, under the CIR program.

Q: What period does the payment relate to?

A: It relates to eligible R&D activities conducted in calendar year 2025.

Q: Which subsidiary qualifies for the CIR?

A: Immutep qualifies through its French subsidiary, Immutep S.A.S.

Q: What will the funding be used for?

A: It will support R&D for eftilagimod alfa (efti) and IMP761.

Q: How long is Immutep's expected cash reach?

A: Immutep expects its cash reach to extend into the first half of CY2028.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.